PHILADELPHIA — (Sept. 6, 2019) — The ARID1A tumor suppressor protein is required to maintain telomere cohesion and correct chromosome segregation after DNA replication. This finding, reported by Wi…
PHILADELPHIA – (SEPT. 4, 2019) – The Wistar Institute, an international leader in biomedical research in cancer, immunology, infectious diseases, and vaccine creation, and IMV Inc. (Nasdaq: IMV; TS…
PHILADELPHIA — (Aug. 21, 2019) — Contrary to the long-held view that semen can only act as a way to transmit HIV-1 from men to women, scientists at The Wistar Institute and the University of Puerto…
PHILADELPHIA — (July, 9, 2019) — Currently, no cure for HIV/AIDS exists, but more than 30 years of scientific advancements in treatment and care made possible because of basic research and clinical…
PHILADELPHIA — (July 3, 2019) —The Wistar Institute, an international leader in biomedical research on cancer, immunology and infectious disease, has received more than $4.2 million in non-federal …
PHILADELPHIA — (July, 2, 2019) — The Wistar Institute, an international biomedical research leader in cancer, immunology, infectious disease and vaccine research, announces the appointment of Rahul…
PHILADELPHIA — (May 22, 2019) — New research from The Wistar Institute sheds light on the function of the ARID1A protein, encoded by a gene that is among the most frequently mutated across human ca…
PHILADELPHIA — (May 15, 2019) — Researchers at The Wistar Institute and the University of South Florida have advanced a novel compound that specifically targets the endoplasmic reticulum (ER) stres…
PHILADELPHIA — (April 23, 2019) — After extensive peer review, The Wistar Institute’s Cancer Center has received an “exceptional” rating on its Cancer Center Support Grant (CCSG) application from t…
PHILADELPHIA — (April 18, 2019) — Wistar scientists have developed a novel synthetic DNA approach for patient-specific production of cancer-targeting molecules called bispecific T cell engagers. DN…
